TOKYO -- Kyorin Holdings likely will enjoy a 10% rise in group operating profit for the year ending in March 2018 as a profitable asthma treatment takes off in Japan.
The Japanese drugmaker looks to log around 11 billion yen ($101 million) in black ink. Sales are seen slipping 3% to 112 billion yen after Kipres, a leading allergy medicine, went off-patent last autumn. Other hot sellers such as an antihistamine are unable to close the ensuing gap.
